

## 1 HOUSE RESOLUTION

2 WHEREAS, The Illinois Department of Public Aid (IDPA) has  
3 entered into a contract to create a Preferred Drug List in  
4 the Medicaid program to entice pharmaceutical manufacturers  
5 into providing supplemental rebates to the program; and

6 WHEREAS, The establishment of a Medicaid Preferred Drug  
7 List will necessitate a vast expansion in prior authorization  
8 of prescription drugs, which inherently limits access of  
9 Medicaid patients to certain prescription medications; and

10 WHEREAS, The creation of an Illinois Medicaid Preferred  
11 Drug List could radically alter the clinical integrity of  
12 formularies and the treatment regimens of Illinois' Medicaid  
13 patients and lead to unintended and costly consequences such  
14 as inferior healthcare, increased hospitalizations and  
15 emergency care, increased admissions into long-term care, and  
16 unnecessary patient suffering and potentially death; and

17 WHEREAS, It could be especially risky to interfere with  
18 the treatment regimens of particularly vulnerable  
19 populations, including, but not limited to, patients with  
20 HIV/AIDS, cancer, or mental illness, children, nursing home  
21 residents, and persons with other complex and serious  
22 diseases; and

23 WHEREAS, IDPA has moved forward on the creation of a  
24 Preferred Drug List without notice to or advice from the  
25 Illinois General Assembly and without input from the patient  
26 advocate community; therefore, be it

27 RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE  
28 NINETY-SECOND GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that  
29 the House Public Aid Preferred Drug List Oversight Committee  
30 is established for the purpose of overseeing the  
31 implementation of IDPA's Medicaid Preferred Drug List; and be

1 it further

2 RESOLVED, That the House Public Aid Preferred Drug List  
3 Advisory Committee shall consist of 5 representatives, 3 of  
4 whom shall be appointed from the majority party by the  
5 Speaker of the House and 2 of whom shall be appointed from  
6 the minority party by the House Minority Leader; and be it  
7 further

8 RESOLVED, That the House Public Aid Preferred Drug List  
9 Oversight Committee may do the following:

10 (1) Hold public hearings to receive and consider  
11 input from key stakeholders such as physicians, the  
12 patient advocacy community, and other interested parties.

13 (2) Solicit data from IDPA and request monthly  
14 reports from IDPA on the implementation, health outcomes,  
15 and net cost implications of the Medicaid Preferred Drug  
16 List, including the cost of any consulting or contractor  
17 fees to implement the Preferred Drug List, the cost to  
18 conduct prior authorization, and costs to other  
19 healthcare services paid for by IDPA, such as emergency  
20 care, hospitalization, and long-term care.

21 (3) Make recommendations to IDPA regarding the  
22 clinical integrity of drug formularies, patient care, and  
23 particular therapeutic classes of drugs that should be  
24 exempted from the Preferred Drug List; and be it further

25 RESOLVED, That the House Public Aid Preferred Drug List  
26 Advisory Committee shall complete its work by December 31,  
27 2002.